| INTRODUCTION
Approximately 5% of variceal bleedings occur outside the cardiooesophageal junction and are denoted as ectopic. 1 Ectopic varices are predominantly located in the small and large intestine and around enterocutaneous stomas, but can also be present in the peritoneum, biliary tree and pelvic organs. 2 Abdominal and pelvic surgery is a well-known risk factor because postoperative adhesions and the creation of an enterostomy facilitate the formation of portosystemic collaterals.
1,2
The management of ectopic variceal bleeding (EctVB) is challenging and not based on the results of controlled trials. Local endoscopic treatment modalities (band ligation, injection sclerotherapy, clips, argon plasma coagulation) and selective variceal embolisation frequently fail to prevent rebleeding with reported recurrence rates up to 80% within 6 months. 3, 4 Surgical treatment, such as local sutures, devascularisation procedures or stoma revision with resiting, will only occasionally provide long-term control of bleeding in selected patients. The creation of surgical portosystemic shunts is associated with significant morbidity and mortality, particularly in patients with decompensated cirrhosis, and is rarely performed nowadays. [5] [6] [7] TIPSS creation is used to treat patients suffering from EctVB. 8 Although evidence suggests that TIPSS is usually effective to prevent recurrent bleeding, research publications are restricted to patient series including only 8-28 patients. [9] [10] [11] [12] [13] Also, variable results have been published with respect to concomitant variceal embolisation, and the additional therapeutic value of embolisation combined with TIPSS placement remains unclear. 9, [11] [12] [13] [14] We therefore aimed, in a multicentre cohort of patients with EctVB, to further determine the efficacy of TIPSS and to evaluate outcomes in subgroups with different types of ectopic varices. We also intended to explore the benefit of concomitant vascular embolisation of collateral vessels feeding the ectopic varices.
| PATIENTS AND METHODS

| Study design and data collection
We included all consecutive patients with advanced chronic liver dis- 
| Definitions
The diagnosis of advanced chronic liver disease was based on liver histology, or a combination of clinical, biochemical and radiological findings. 15 The model for end-stage liver disease (MELD) score was calculated with the formula: 0.957 × log(creatinine in mg/dL) + 0.378 × log(bilirubin in mg/dL) + 1.120 × log(INR) + 0.643. 16, 17 Comorbidity with a cardiovascular condition, pulmonary condition or renal condition was defined as a condition requiring long-term medical treatment for which regular specialist follow-up care was necessary. Early TIPSS was defined as TIPSS insertion within 72 hours after an EctVB episode. 18 Bleeding was defined as a decrease in haemoglobin (Hb) by 2 g/dL (1.24 mmol/L), or the requirement of more than 2 units of packed red cells within 24 hours to stabilise
Hb concentration or signs of volume depletion (systolic blood pressure below 100 mm Hg and/or heart rate above 100/min).
13
Rebleeding was defined as a single episode of clinical significant recurrent melena or hematemesis from portal hypertensive sources after day 5 that resulted in any of the following: (a) hospital admis- 
| Statistical analysis
Continuous variables were reported as mean with standard deviation (SD), after visual confirmation of approximate normality, and compared using a T test. A median and range from the first to the third quartile (IQR, interquartile range) was computed for continuous variables with a non-normal distribution and compared using a MannWhitney test. Categorical variables were reported as count with proportion and compared using the chi-squared test.
The actuarial probabilities of being free of shunt dysfunction (shunt dysfunction as event, censoring at death or liver transplantation), being free of rebleeding (rebleeding as event, censoring at death or liver transplantation) and transplant-free survival (death as event, censoring at liver transplantation) after TIPSS creation were estimated using the Kaplan-Meier method and compared using logrank tests.
A univariable Cox regression analysis was carried out to identify risk factors for rebleeding at TIPSS placement using candidate predictor variables, hereinafter mentioned, as described in the literature and based on the clinical and research experiences of co-investigators: MELD score, location of EctVB, local treatment of the EctVB, urgency placement of TIPSS, type of stent used during TIPSS, portal pressure gradient after TIPSS placement above 12 mm Hg and concomitant embolisation. 2, [11] [12] [13] 18, 21, 22 The univariable Cox regression models were adjusted with a propensity score to take into account differences in MELD score at TIPSS placement for each individual covariate.
Furthermore, the effect of concomitant embolisation during the TIPSS procedure compared to TIPSS alone on rebleeding and mortality was analysed. For this analysis as well, a propensity score was calculated using a logistic regression model, estimating the probability to receive concomitant embolisation given the following observed baseline characteristics: MELD score, location of EctVB, type of stent used during TIPSS and urgency placement of TIPSS as predictor variables.
A two-sided P < 0.05 was considered significant for descriptive statistics, and a P-value <0.10 was considered significant for univariable regression models. All statistical analyses were performed using IBM SPSS Statistics for Windows, version 24.0 (IBM Corp., Armonk, NY, USA).
| RESULTS
| Patient characteristics and TIPSS procedures
In the three centres, 53 patients received TIPSS for EctVB during the study period, representing 5.4% of the total population (n = 979) undergoing a TIPSS procedure ( Figure 1 ). The study population consisted predominantly of males with a median age of 61 years (IQR 51-66) and a median MELD score of 11 (IQR 9-17; Table 1 ). The ectopic varices were most often located near the mucocutaneous junction of stomas (40%), followed by the duodenum (23%), rectum (17%) and other sites (20%). TIPSS placement was the initial treatment for EctVB in 23% of the patients. About 77% of the patients had been unsuccessfully treated for EctVB with one or multiple modalities; 24 patients (45%) had undergone previous endoscopic treatment (band ligation, injection therapy, coagulation), 22 (42%)
had received vasoactive medication (nonselective beta-blockers, somatostatin, terlipressin), 9 (17%) had undergone abdominal surgery (stoma revision or relocation, bowel resection) and 1 patient (2%)
had received endovascular treatment (embolisation).
TIPSS were created with a bare metal stent in 8 patients and
with an e-PTFE-covered stent in 45 patients (Table 2) . Hemodynamic measurements showed that the median pre-TIPSS portosystemic gradient (PSG) decreased from 14 mm Hg (IQR 10-20) to 6 mm Hg (IQR 4-7) after TIPSS placement. The post-TIPSS PSG remained above 12 mm Hg in four patients. Eighteen (34%) patients received early TIPSS and initial hemostasis was achieved in all cases.
| Clinical outcome
The with stomal EctVB (P < 0.001) ( Figure S1 ).
TIPSS dysfunction was diagnosed in 6 of 8 patients with bare metal stents (75%) compared to 10 of 45 with e-PTFE-covered stents (22%) (P = 0.011). In six patients, shunt dysfunction was diagnosed at an elective follow-up visit and in nine patients after a rebleed. Most shunt dysfunctions were diagnosed in the first 6 months after TIPSS creation, in seven patients in the first month (13%), in 6 after 1-6 months (11%) and in three after 6 months (6%).
The estimated cumulative TIPSS dysfunction rate significantly dif- were 11%, 41% and 75%, respectively ( Figure S2 ).
| Concomitant embolisation during TIPSS
Concomitant embolisation during the TIPSS procedure was performed in 13 patients: four patients had varices located near enterocutaneous stomas, four had duodenal varices, two had rectal varices, two had intraperitoneal varices and one had varices in the ascending colon.
Concomitant embolisation was performed in 4 of 9 patients with an acute bleeding and in 9 of 44 patients as a secondary prophylactic measure. There were no statistically significant differences between patients receiving embolisation and TIPSS alone with respect to age, gender, MELD score, location of varices, presentation with acute bleeding or treatment centre. After propensity score adjustment, the hazard ratio for rebleeding of concomitant embolisation compared to TIPSS alone was 0.701 (95% CI: 0.145-3.390; P = 0.659) and the hazard ratio for mortality was 0.776 (95% CI: 0.281-2.148; P = 0.626).
| DISCUSSION
This multicentre cohort study evaluated the efficacy of TIPSS with predominantly e-PTFE-covered stents in subgroups of patients with bleeding from ectopic varices. The present study confirms that TIPSS was an effective treatment by completely preventing rebleeding in the large majority (77%) of cases. TIPSS was particularly effective in patients with less severe liver disease and with varices located at enterostomas. In contrast, the rebleeding risk in patients with duodenal varices was unexpectedly high.
The observed cumulative 23% rebleeding rate at 1 year is comparable with previously reported rates varying from 23% to 39%, [11] [12] [13] while the 26% rate at 2 years was considerably lower than previously reported. 12 It seems likely that the superior long-term bleeding control is attributable to the use of e-PTFE-covered stents in the large majority of cases. The actuarial risk of remaining free from rebleeding in the present series in comparison with the risk observed in TIPSS-treated gastro-oesophageal bleeding reported in two recently published studies originating from the participating centres was 77% versus 94-100% at 1 year, 74% versus 92-94% at 3 years and 68% versus 90-92% at 5 years, respectively. 22, 23 Thus, the overall rebleeding risk in TIPSS-treated EctVB appears to be OEY ET AL.
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higher than that in gastro-oesophageal bleeding. Our data indicate that this seems attributable to the relevant high rebleeding risk in TIPSS-treated duodenal EctVB.
In our cohort, shunt dysfunction was diagnosed in three-quarter of the patients with rebleeding and occurred three times more often in bare metal stents compared to e-PTFE-covered stents. In total, 12, 13 Although these rates vary notably, the trend that e-PTFE-covered stents have improved shunt patency is in line with widely reported experience. 24, 25 In our series, the efficacy of TIPSS in patients with duodenal
EctVB, who had a disappointing 50% rebleeding risk, was relatively poor. A potential explanatory factor may be that local, but ultimately unsuccessful endoscopic therapies frequently preceded TIPSS. In our experience, endoscopic treatment, in particular repeated tissue glue injections, may lead to significant duodenal ulcerations that can be the cause of repeated bleeding in their own right. In such cases, it may be very difficult to distinguish portal hypertensive-related bleeding from other causes, and management may be troublesome.
Another possibility is that local tumorous vascular ingrowth or thrombosis could cause (re)bleeding unrelated to portal hypertension.
However, in our two cases with duodenal variceal bleeding and a previous diagnosis of pancreatic cancer, there was no evidence for residual or recurrent tumour. Also with respect to other malignancies, there was no indication that these were of aetiological importance. Further studies in this type of EctVB are required to further address the timing of TIPSS and whether alternative therapeutic approaches, in particular balloon-occluded retrograde-transvenousobliteration may be a preferable strategy. 26 The efficacy of TIPSS has to be balanced against the risk of serious side effects, in particular HE. Post-TIPSS HE manifested or worsened in 30% of our patients, which was comparable with other reported experience. 18, 23, 27, 28 The majority of post-TIPSS HE could be managed medically, but in some cases, a stent diameter reduction was necessary. A recent report suggests that there might be an optimum of 8 mm TIPSS diameter to effectively decompress the portal system in relation to the encephalopathy risk. 29 With the knowledge that the diameter of TIPSS can passively increase after placement, improved results regarding post-TIPSS HE may be expected in the future for diameter controlled expansion stents.
30,31
A recent meta-analysis found a nonsignificant trend towards a beneficial effect of variceal embolisation in addition to TIPSS. 14 Our data are in line with these results as embolisation did not significantly improve the probability of remaining free of rebleeding or survival. However, considering the potential selection bias occurring when embolisation of the culprit varix is not feasible and the limited number of patients treated, we were unable to reliably assess the value of embolisation as an adjunctive measure.
To the best of our knowledge, we report the largest multicentre cohort of patients with TIPSS for EctVB with predominantly e-PTFE-covered stents and our data reflect real-life practice in three university hospitals. Despite the retrospective study design, only one patient was lost to follow-up. This is the first study allowing a preliminary assessment of the efficacy of TIPSS in subgroups of
EctVB, although the results should be interpreted cautiously considering the size of the patient population. Ideally, prospective trials could provide more clarity about the role of TIPSS in subgroups of EctVB as well as on the role of concomitant embolisation. However, such studies may never be performed considering the low prevalence of the disease, the heterogeneity in varices location and the technical inability to embolise all culprit collateral vessels.
In conclusion, our study demonstrates that TIPSS effectively prevents rebleeding in the majority of patients presenting with EctVB.
TIPSS is particularly effective in bleeding from enterostomas, the most frequent type of EctVB. However, the results in duodenal Time after TIPSS (y)
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